Skip to main content

1 Result(s)

within Article Remove this filter Yoshimasa Shiraishi Remove this filter Biomedicine, general Remove this filter Drug Resistance Remove this filter

and

  1. No Access

    Article

    Association of immune-related adverse events with durvalumab efficacy after chemoradiotherapy in patients with unresectable Stage III non-small cell lung cancer

    Immune-related adverse events (irAEs) have been found to predict PD-L1 inhibitor efficacy in metastatic NSCLC. However, the relation of irAEs to clinical outcome for nonmetastatic NSCLC has remained unknown.

    Koji Haratani, Atsushi Nakamura, Nobuaki Mamesaya, Kenji Sawa… in British Journal of Cancer (2024)